Matt, Author at European Medical Journal - Page 121 of 212

Perinatal Hepatitis C Linked to Earlier Cirrhosis Development

Hepatitis C virus (HCV) infection during the perinatal period leads to the earlier development of cirrhosis, suggests new research from Birmingham…

Advancements and Trends in Urology

EMJ Urology Editorial Board member Dr Alan Wein has enjoyed a long and distinguished career in healthcare, having been at the heart of numerous…

Pelvic Floor Exercises and Overactive Bladder

Pelvic floor muscle (PFM) training is commonly used to control overactive bladder, which is a very common form of urinary incontinence. The results of a…

New Genes Linked to Prostate Cancer

Prostate cancer is considered a major health concern, with >1 million new cases diagnosed every year and the disease claiming 300,000 lives each year…

INet NYC: Support for International Scientists

This interview is with Jess Sharrock, Social Media Manager at International Networking in New York City (INet NYC), New York, USA, an organisation that…

The Lancet Asthma Commission: Towards the Abolition of Asthma?

The more widespread use of inhaled corticosteroids (ICS) for the treatment of asthma following guideline recommendations 27 years ago1,2 delivered huge…

Translating Knowledge of IL-23 Targeting into New Solutions for Psoriasis Treatment

Following a brief introduction by Prof Lambert, the symposium started with an in-depth review of the current unmet needs in the clinical management of…

Type 2 Inflammation and the Evolving Profile of Uncontrolled Persistent Asthma

The objective of this symposium was to provide an overview of Type 2 inflammation in asthma. The speakers covered the pathophysiology of Type 2 asthma, its heterogeneity and the associated economic burden.

Management of Fluctuating Parkinson’s Disease: From Science to Clinical Wisdom

This symposium took place at the 4th Congress of the European Academy of Neurology (EAN) 2018 in Lisbon, Portugal, and focussed on the effective…

Editor’s Pick: Newest Approaches in Immunotherapy for Non-Hodgkin’s Lymphoma

Immunotherapy has revolutionised the treatment of haematologic malignancies. Patients with relapsed/refractory non-Hodgkin’s lymphoma have poor response…